JPWO2020212553A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020212553A5
JPWO2020212553A5 JP2021561852A JP2021561852A JPWO2020212553A5 JP WO2020212553 A5 JPWO2020212553 A5 JP WO2020212553A5 JP 2021561852 A JP2021561852 A JP 2021561852A JP 2021561852 A JP2021561852 A JP 2021561852A JP WO2020212553 A5 JPWO2020212553 A5 JP WO2020212553A5
Authority
JP
Japan
Prior art keywords
cyclopropyl
difluorophenyl
amine
purin
propylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021561852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529052A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/060819 external-priority patent/WO2020212553A1/en
Publication of JP2022529052A publication Critical patent/JP2022529052A/ja
Publication of JPWO2020212553A5 publication Critical patent/JPWO2020212553A5/ja
Pending legal-status Critical Current

Links

JP2021561852A 2019-04-18 2020-04-17 グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体 Pending JP2022529052A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170003 2019-04-18
EP19170003.8 2019-04-18
EP19188639 2019-07-26
EP19188639.9 2019-07-26
PCT/EP2020/060819 WO2020212553A1 (en) 2019-04-18 2020-04-17 New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling

Publications (2)

Publication Number Publication Date
JP2022529052A JP2022529052A (ja) 2022-06-16
JPWO2020212553A5 true JPWO2020212553A5 (ko) 2023-04-24

Family

ID=70480222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561852A Pending JP2022529052A (ja) 2019-04-18 2020-04-17 グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体

Country Status (9)

Country Link
US (1) US20210290625A1 (ko)
EP (1) EP3955929B1 (ko)
JP (1) JP2022529052A (ko)
KR (1) KR20220003556A (ko)
CN (1) CN113329753A (ko)
AU (1) AU2020258017A1 (ko)
BR (1) BR112021012834A2 (ko)
CA (1) CA3128304A1 (ko)
WO (1) WO2020212553A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4928399A (en) * 1998-07-27 2000-02-21 M & M Laboratory Co., Ltd. Ion complex, coating material, and coating method
AU2003265636A1 (en) * 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
DE102005060690B4 (de) * 2005-12-15 2008-09-25 Capsulution Nanoscience Ag Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
EP2236158A1 (en) * 2009-03-30 2010-10-06 Pharnext New therapeutic approaches for treating neuroinflammatory conditions
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
ES2731658T3 (es) * 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection

Similar Documents

Publication Publication Date Title
MX2010001677A (es) Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
JP2016527217A5 (ko)
JP2020507589A5 (ko)
JP2008509187A5 (ko)
CY1113670T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης
JP2005536475A5 (ko)
JP2018524298A5 (ko)
RU2012110007A (ru) Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor
JP2015502974A5 (ko)
RU2015117267A (ru) Замещенные соединения амида
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
JP2010533160A5 (ko)
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2016506959A5 (ko)
RU2008142841A (ru) СОЕДИНЕНИЯ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЙ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ ГАМКА РЕЦЕПТОРОВ
RU2008115239A (ru) 7-[2-[4-(6-фтор-3-метил-1, 2-бензизоксазол-5-ил)-1-пиперазинил]этил]-2-(пропинил)-7h-пиразоло-[4,3-е]-[1,2,4]-триазоло-[1,5-с]пиримидин-5-амин
JP2015535247A5 (ko)
ATE402707T1 (de) Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2013507426A5 (ko)
IL276013B1 (en) PI4KIIIBETA inhibitors
CO5200847A1 (es) Metodos y composiciones para tratar enfermedades y condiciones del ojo
JP2018522049A5 (ko)
TW200626609A (en) 8-position modified purine nucleoside derivatives and medicinal use thereof